$XBI $84.32 | +0.67%
Covid Updates
Pipeline Updates
$AFMD +1.5% Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research source
$RUBY +4.4% Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting source
$CARA +11.0% Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting source
$ATOS +4.2% Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen. source
$ANVS +5.6% Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022. source
$RDUS +5.6% Radius Health Provides Business Update on Bone Health. source
$BNTX +1.5% BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC. source
$RVNC +5.6% Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA. source
$ALDX +8.8% Aldeyra Therapeutics Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa. source
$RIGL +1.3% Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology. source
$CRTX +8.2% Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588. source
$PHAS -2.7% PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update. source
$SEEL +0.8% Seelos Therapeutics Receives an Acknowledgement Letter of a Clinical Trial Notification from the Australian Government Department of Health Therapeutic Goods Administration for a Pilot Study of SLS-005 in Alzheimer's Disease. source
$EWTX +2.1% Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference. source
$KALA +88.5% Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare. source
$IFRX +0.5% InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting. source
$BBIO +4.3% BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRY™ (Fosdenopterin). source
$CALA +3.1% Calithera to Present Data Highlighting Newly Discovereds ynthetic Lethal Target VPS4 at AACR 2022 Annual Meeting. source
$ALEC -9.7% Alector to Present New AL001 Data at AD/PD™ 2022. source
$IDYA 0.0% IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update. source
$VYGR +33.3% Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs. source
Business Updates
$MBIO +2.3% Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital. source
Posted by FS/JM
Comentários